Isotope-differentiated binding energy shift tags (IDBEST™) for improved targeted biomarker discovery and validation

Expert Review of Proteomics

Volumn 1, Issue 4, 2004, Pages 421-431

  Hall, Michael P ^a   Schneider, Luke V ^a  

^a Target Discovery Inc   (United States)

Author keywords

Affinity enrichment; Biomarkers; Isoforms; MALDI TOF; Mass defect; Stable isotope; Tagging

Indexed keywords

BIOLOGICAL MARKER; PEPTIDE; PROTEIN; PEPTIDE LIBRARY;

BIOMASS PRODUCTION; DOWN REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE DIFFERENTIATED BINDING ENERGY SHIFT TAG; MASS SPECTROMETER; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; UPREGULATION; VALIDATION PROCESS; ARTICLE; CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CHROMATOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; ISOTOPE LABELING; MASS SPECTROMETRY; PEPTIDE LIBRARY; PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 14644392991     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.1.4.421     Document Type: Review

References (43)

1. Rubenstein K. Post-Genomic Markers: Revolutionizing Drug Development and Diagnostics. D&MD Publications, MA, USA (2003). Excellent overview of the biomarker market with respect to both technical and business sectors.
2. Wind M, Reines D. Transcription elongation factor SII. Bioessays 22, 327-336 (2000).
3. Tavaria M, Gabriele T, Kola I, Anderson RL. A hitchhiker's guide to the human Hsp70 family. Cell Stress Chaperones 1, 23-28 (1996).
4. Strittmatter WJ. Apolipoprotein E and Alzheimer's disease: signal transduction mechanisms. Biochem. Soc. Symp. 67, 101-109 (2001).
5. Prusiner SB, Gabizon R, McKinley MP. On the biology of prions. Acta Neuropathol. (Berl.) 72, 299-314 (1987).
6. Yu HL, Chertkow HM, Bergman H, Schipper HM. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 3, 2240-2248 (2003).
7. Rich S, McLaughlin W. Endothelin receptor blockers in cardiovascular diseases. Circulation 108, 2184-2190 (2003).
8. Hanna AN, Waldman WJ, Lott JA, Koesters SC, Hughes AM, Thornton DJ. Increased alkaline phosphatase isoforms in autoimmune diseases. Clin. Chem. 43, 1357-1364 (1997).
9. Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J. Biochem. Mol. Biol. 36, 49-59 (2003).
10. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24, 218-219 (2003).
11. Peracaula R, Tabares G, Royle L et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 13, 457-470 (2003). Excellent example of the importance of the analysis of biomarker isoforms for highest clinical specificity and correlation to disease diagnosis and disease progression.
12. Rys J, Kruczak A, Lackowska B et al. The role of CD44v3 expression in female breast carcinomas. Pol. J. Pathol. 54, 243-247 (2003).
13. Nakagawa M, Emoto A, Nasu N et al. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J. Urol. 157, 1260-1264 (1997).
14. Piver B, Fer M, Virac X et al. Cytochrome P450 isoforms critical to drug metabolism and clearance. Biochem. Pharmacol. 68, 773-782 (2004).
15. Stewart II, Zhao L, Le Bihan T et al. The reproducible acquisition of comparative liquid chromatography/tandem mass spectrometry data from complex biological samples. Rapid Commun. Mass Spectrom. 18, 1697-1710 (2004).
16. 18O-labeled internal standards. Rapid Comm. Mass Spectrom. 14, 1226-1232 (2000).
17. 18O labeling: a tool for proteomics. Rapid Commun. Mass Spectrom. 15, 2456-2465 (2001). Good example of initial studies utilizing stable isotopes for quantitation of peptides in the mass spectrometer.
18. Ren D, Penner NA, Slentz BE, Regnier FE. Histidine-rich peptide selection and quantification in targeted proteomics. J. Prot. Res. 3, 37-45 (2004).
19. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnol. 17, 994-999 (1999). Describes the use of isotope-coded affinity tags, a methodology in wide use today for doing bottom-up proteomic profiling.
20. Varnum SM, Covington CC, Woodbury RL et al. Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res. Treat. 80, 87-97 (2003).
21. Sauter ER, Daly M, Linahan K et al. Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 5, 967-970 (1996).
22. Kenyon GL, DeMarini DM, Fuchs E et al. Defining the mandate of proteomics in the post-genomics era. Mol. Cell. Proteomics 1, 763-780 (2002).
23. Ingraham JL, Maaløe O, Neidhardt FC. Growth of the Bacterial Cell. Sinauer Associates, MA, USA (1983).
24. Creighton TE. Proteins: Structures and Molecular Properties. WH Freeman & Company, NY, USA (1993).
25. Schwartz SA, Weil RJ, Johnson MD, Toms SA, Caprioli RM. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin. Cancer Res. 10, 981-987 (2004).
26. Schwartz SA, Reyzer ML, Caprioli RM. Direct tissue analysis using matrix-assisted laser desorption/ionization mass spectrometry: practical aspects of sample preparation. J. Mass Spectrom. 38, 699-708 (2003).
27. Yu Y, Ji H, Doudna JA, Leary JA. Top down and bottom up MS identification of the human 40S ribosomal proteins. 52nd American Society for Mass Spectrometry Conference, TN, USA (2004).
28. Kiernan UA, Nedelkov D, Tubbs KA, Niederkofler EE, Nelson RW. Proteomic characterization of novel serum amyloid P component variants from human plasma and urine. Proteomics 4, 1825-1829 (2004).
29. Kelleher, NL. Top-down proteomics. Anal. Chem. 76, 197A-2003A (2004). Excellent review of the current technologies, successes, and challenges of top-down proteomics.
30. Hall MP, Ashrafi S, Obegi I, Petesch R, Peterson JN, Schneider LV. 'Mass defect' tags for biomolecular mass spectrometry. J. Mass Spectrom. 38, 809-816 (2003). Describes the general use and power of mass defect tagging in various biomolecular mass spectrometric methodologies, including IDBEST™ (Target Discovery, Inc.).
31. Sauter ER, Zhu W, Fan X-J, Wassell RP, Chervoneva I, Du Bois GC. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br. J. Cancer 86, 1440-1443 (2002).
32. Nelson RW, Krone JR, Bieber AL, Williams P. Mass spectrometric immunoassay. Anal. Chem. 67, 1153-1158 (1995).
33. Nedelkov D, Nelson RW, Kiernan UA, Niederkofler EE, Tubbs KA. Detection of bound and free IGF-1 and IGF-2 in human plasma via biomolecular interaction analysis mass spectrometry. FEBS Lett. 536, 130-134 (2003). Good example of the benefits of top-down affinity-based biomarker characterization.
34. McLaffeny FW, Kelleher NL, Begley TP, Fridriksson EK, Zubarev RA, Horn DM. Two-dimensional mass spectrometry of biomolecules at the subfemtomole level. Curr. Opin. Chem. Biol. 2, 571-578 (1998).
35. Schneider LV, Hall MP, Brasseur MM. Mass-defect tagging for proteomic analysis. Genetic Eng. News 24, 28-30 (2004).
36. Bucche F. Principles of Physics. McGraw-Hill, NY, USA (1977).
37. Felinger A, Pietrogrande MC. Decoding complex multicomponent chromatrograms. Anal. Chem. 73, 619A-623A (2001).
38. Yousef GM, Scorilas, A, Maglklara A et al. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br. J. Cancer 87, 1294-1300 (2002).
39. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. 2, 257-280 (2004).
40. Sauter ER, Klein G, Wagner-Mann C, Diamandis EP. Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer. Cancer Det. Prev. 28, 27-31 (2004).
41. Peptide homology search performed by Zymed Laboratories, Inc., CA, USA (2004).
42. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845-867 (2002).
43. Halligan BD, Dratz E. The Qcomp method for rapid peptide identification using qualitative amino acid composition and peptide mass. Keystone Symposia, Mass Spectrometry in Systems Biology, NM, USA (2004).